Intra-arterial (Ophthalmic Artery) Chemotherapy for Retinoblastoma

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually safe. In recent years, there has been much interest in providing highly focused (focal) chemotherapy to a diseased organ including the liver, brain, and eye. With focused chemotherapy, the chemotherapy drugs are injected directly into the ophthalmic artery (the artery that supplies blood to the eye). A benefit of focal chemotherapy delivery is that it decreases the chance of toxicity to other organs such as bone marrow suppression (causing low blood counts) and the development of other cancers in the future.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: No
View:

• Advanced retinoblastoma in one or both eyes

• Recurrent retinoblastoma after failure of previous treatment

• No age limit (usually kids presenting with retinoblastoma present in the 1st two decades of life)

• Judged by principal investigator to be medically and physically able to undergo the procedure

Locations
United States
Pennsylvania
Oncology Service, Wills Eye Institute
Philadelphia
Time Frame
Start Date: January 2009
Completion Date: April 2014
Participants
Target number of participants: 10
Treatments
Experimental: Chemotherapy
Chemotherapy using Melphalan, Carboplatin.
Sponsors
Leads: Wills Eye
Collaborators: Thomas Jefferson University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials